Cellular tests for the evaluation of drug hypersensitivity

Current Pharmaceutical Design

Volumn 22, Issue 45, 2016, Pages 6773-6783

  Ariza, Adriana ^a   Montañez, Maria I ^a,b   Fernández, Tahia D ^a   Perkins, James R ^a   Mayorga, Cristobalina ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

Author keywords

Basophils; Diagnosis; Drug hypersensitivity; IgE; In vitro tests; Lymphocytes

Indexed keywords

DRUG METABOLITE; IMMUNOGLOBULIN E; LEUKOTRIENE; ANTIINFECTIVE AGENT;

BASOPHIL ACTIVATION TEST; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HISTAMINE RELEASE; HISTAMINE RELEASE TEST; IMMUNE FUNCTION TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKOTRIENE RELEASE TEST; LYMPHOCYTE TRANSFORMATION TEST; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SKIN TEST; HUMAN; IMMUNOLOGY; T LYMPHOCYTE;

ANTI-BACTERIAL AGENTS; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; SKIN TESTS; T-LYMPHOCYTES;

EID: 85012042844     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666161107165917     Document Type: Review

References (149)

1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113(5): 832-6.
2. Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin North Am 2004; 24(3): 345-56, v.
3. Sanchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin North Am 2010; 94(4): 853-64, xiii.
4. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011; 71(5): 684-700.
5. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5(4): 309-16.
6. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003; 90(3): 342-7.
7. Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58(10): 961-72.
8. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139(8): 683-93.
9. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59(11): 1153-60.
10. Chiriac AM, Demoly P. Drug allergy diagnosis. Immunol Allergy Clin North Am 2014; 34(3): 461-71, vii.
11. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011; 127(3 Suppl): S67-73.
12. Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013; 68(10): 1219-32.
13. Dona I, Barrionuevo E, Blanca-Lopez N, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol 2014; 24(3): 143-53; quiz 1 p following 53.
14. Valdivieso R, Canarte C. It is not a fixed drug eruption, it is a fixed “sunlight” eruption. Int J Dermatol 2010; 49(12): 1421-3.
15. Uetrecht J. Immune-mediated adverse drug reactions. Chem Res Toxicol 2009; 22(1): 24-34.
16. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol 2013; 25(1): 81-9.
17. Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J 2008; 1(6): 96-102.
18. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61(5): 643-56.
19. Martin SF, Esser PR, Schmucker S, et al. T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci 2010; 67(24): 4171-84.
20. Blanca M, Mayorga C, Perez E, et al. Determination of IgE antibodies to the benzyl penicilloyl determinant. A comparison between poly-L-lysine and human serum albumin as carriers. J Immunol Methods 1992; 153(1-2): 99-105.
21. Mayorga C, Obispo T, Jimeno L, et al. Epitope mapping of betalactam antibiotics with the use of monoclonal antibodies. Toxicology 1995; 97(1-3): 225-34.
22. Edwards RG, Dewdney JM, Dobrzanski RJ, Lee D. Immunogenicity and allergenicity studies on two beta-lactam structures, a clavam, clavulanic acid, and a carbapenem: structureactivity relationships. Int Arch Allergy Appl Immunol 1988; 85(2): 184-9.
23. Christie G, Park BK. Disposition and immunogenicity of penicillin in the rabbit. Int Arch Allergy Appl Immunol 1989; 89(2-3): 162-8.
24. Jenkins RE, Meng X, Elliott VL, et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009; 3(6): 720-9.
25. Meng X, Jenkins RE, Berry NG, et al. Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. J Pharmacol Exp Ther 2011; 338(3): 841-9.
26. Liyasova MS, Schopfer LM, Lockridge O. Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545. Biochem Pharmacol 2010; 79(5): 784-91.
27. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol 2011; 187(1): 200-11.
28. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57(2): 727-39.
29. Ariza A, Garzon D, Abanades DR, et al. Protein haptenation by amoxicillin: high resolution mass spectrometry analysis and identification of target proteins in serum. J Proteomics 2012; 77(504-20.
30. Manchanda T, Hess D, Dale L, Ferguson SG, Rieder MJ. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol 2002; 62(5): 1011-26.
31. Naisbitt DJ, Nattrass RG, Ogese MO. In vitro diagnosis of delayedtype drug hypersensitivity: mechanistic aspects and unmet needs. Immunol Allergy Clin North Am 2014; 34(3): 691-705, x.
32. Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57(1): 45-51.
33. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58(9): 854-63.
34. Benahmed S, Picot MC, Dumas F, Demoly P. Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med 2005; 165(13): 1500-5.
35. Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64(2): 183-93.
36. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs--an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68(6): 702-12.
37. Demoly P, Lebel B, Messaad D, et al. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 1999; 54(5): 500-6.
38. Mata E, Gueant JL, Moneret-Vautrin DA, et al. Clinical evaluation of in vitro leukocyte histamine release in allergy to muscle relaxant drugs. Allergy 1992; 47(5): 471-6.
39. Pineda F, Ariza A, Mayorga C, et al. Role of histamine release test for the evaluation of patients with immediate hypersensitivity reactions to clavulanic acid. Int Arch Allergy Immunol 2015; 168(4): 233-40.
40. Gamboa PM, Sanz ML, Caballero MR, et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003; 58(4): 312-7.
41. De Week AL, Sanz ML, Gamboa PM, et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. J Investig Allergol Clin Immunol 2009; 19(2): 91-109.
42. Torres MJ, Padial A, Mayorga C, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy 2004; 34(11): 1768-75.
43. Sanz ML, Gamboa PM, Antepara I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32(2): 277-86.
44. Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010; 125(2): 502-05 e2.
45. Sanchez-Morillas L, Perez-Ezquerra PR, Reano-Martos M, et al. Selective allergic reactions to clavulanic acid: a report of 9 cases. J Allergy Clin Immunol 2010; 126(1): 177-9.
46. Abuaf N, Rajoely B, Ghazouani E, et al. Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol 1999; 104(2 Pt 1): 411-8.
47. Monneret G, Benoit Y, Debard AL, et al. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol 2002; 102(2): 192-9.
48. Ebo DG, Bridts CH, Hagendorens MM, et al. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006; 61(8): 935-9.
49. Gomez E, Blanca-Lopez N, Torres MJ, et al. Immunoglobulin Emediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009; 39(8): 1217-24.
50. Rouzaire P, Nosbaum A, Denis L, et al. Negativity of the basophil activation test in quinolone hypersensitivity: a breakthrough for provocation test decision-making. Int Arch Allergy Immunol 2012; 157(3): 299-302.
51. Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgEmediated hypersensitivity reactions to quinolones. Allergy 2011; 66(2): 247-54.
52. Ben Said B, Berard F, Bienvenu J, Nicolas JF, Rozieres A. Usefulness of basophil activation tests for the diagnosis of IgEmediated allergy to quinolones. Allergy 2010; 65(4): 535-6.
53. Seitz CS, Brocker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clin Exp Allergy 2009; 39(11): 1738-45.
54. Pinnobphun P, Buranapraditkun S, Kampitak T, Hirankarn N, Klaewsongkram J. The diagnostic value of basophil activation test in patients with an immediate hypersensitivity reaction to radiocontrast media. Ann Allergy Asthma Immunol 2011; 106(5): 387-93.
55. Salas M, Gomez F, Fernandez TD, et al. Diagnosis of immediate hypersensitivity reactions to radiocontrast media. Allergy 2013; 68(9): 1203-6.
56. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991; 88(3 Pt 1): 328-38.
57. Ebo DG, Leysen J, Mayorga C, et al. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2011; 66(10): 1275-86.
58. Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 2015; 70(11): 1393-405.
59. Buhring HJ, Simmons PJ, Pudney M, et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999; 94(7): 2343-56.
60. Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for Drug Hypersensitivity Reactions. An ENDA/EAACI Drug Allergy Interest Group Position Paper. Allergy 2016; 71(8): 1103-34.
61. Uyttebroek AP, Sabato V, Leysen J, et al. Flowcytometric diagnosis of atracurium-induced anaphylaxis. Allergy 2014; 69(10): 1324-32.
62. Uyttebroek AP, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Moxifloxacin hypersensitivity: Uselessness of skin testing. J Allergy Clin Immunol Pract 2015; 3(3): 443-5.
63. Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29(11): 1087-100.
64. Bavbek S, Ikinciogullari A, Dursun AB, et al. Upregulation of CD63 or CD203c alone or in combination is not sensitive in the diagnosis of nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol 2009; 150(3): 261-70.
65. Celik GE, Schroeder JT, Hamilton RG, Saini SS, Adkinson NF. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy 2009; 39(10): 1522-31.
66. Korosec P, Mavsar N, Bajrovic N, et al. Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance. Int Arch Allergy Immunol 2011; 155(3): 257-62.
67. Ariza A, Fernandez TD, Dona I, et al. Basophil activation after nonsteroidal anti-inflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs. Cytometry A 2014; 85(5): 400-7.
68. De Weck AL, Sanz ML, Gamboa PM, et al. Nonsteroidal antiinflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J Investig Allergol Clin Immunol 2009; 19(5): 355-69.
69. Hagau N, Longrois D, Petrisor C. Threshold for positivity and optimal dipyrone concentration in flow cytometry-assisted basophil activation test. Allergy Asthma Immunol Res 2013; 5(6): 383-8.
70. Trcka J, Schmidt C, Seitz CS, et al. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol 2008; 190(3): 666-70.
71. Miura K, MacGlashan DW. Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils. Blood 2000; 96(6): 2199-205.
72. Mochizuki A, McEuen AR, Buckley MG, Walls AF. The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation. J Allergy Clin Immunol 2003; 112(1): 102-8.
73. Knol EF, Koenderman L, Mul FP, Verhoeven AJ, Roos D. Differential activation of human basophils by anti-IgE and formylmethionyl-leucyl-phenylalanine. Indications for protein kinase Cdependent and-independent activation pathways. Eur J Immunol 1991; 21(4): 881-5.
74. Ariza A, Garcia-Martin E, Salas M, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Sci Rep 2016; 6: 23845.
75. Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008; 38(6): 921-8.
76. Sudheer PS, Hall JE, Read GF, Rowbottom AW, Williams PE. Flow cytometric investigation of peri-anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia 2005; 60(3): 251-6.
77. Uyttebroek AP, Sabato V, Bridts CH, Ebo DG. In vitro diagnosis of immediate IgE-mediated drug hypersensitivity: warnings and (unmet) needs. Immunol Allergy Clin North Am 2014; 34(3): 681-9, x.
78. Mayorga C, Andreu I, Aranda A, et al. Fluoroquinolone photodegradation influences specific basophil activation. Int Arch Allergy Immunol 2013; 160(4): 377-82.
79. Fernández TD, Ariza A, Palomares F, et al. Hypersensitivity to fluoroquinolones. The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. Medicine 2016; 95(23): e3679.
80. de Weck AL, Sanz ML, Gamboa PM, et al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy Immunol 2008; 146(3): 177-89.
81. Fernandez TD, Torres MJ, Blanca-Lopez N, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009; 64(2): 242-8.
82. Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006; 61(3): 311-5.
83. Sanz ML, Gamboa PM, Mayorga C. Basophil activation tests in the evaluation of immediate drug hypersensitivity. Curr Opin Allergy Clin Immunol 2009; 9(4): 298-304.
84. Torres MJ, Ariza A, Fernandez J, et al. Role of minor determinants of amoxicillin in the diagnosis of immediate allergic reactions to amoxicillin. Allergy 2010; 65(5): 590-6.
85. Torres MJ, Mayorga C, Fernandez TD, et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol 2006; 19(1): 119-30.
86. Tsuge I, Okumura A, Kondo Y, et al. Allergen-specific T-cell response in patients with phenytoin hypersensitivity; simultaneous analysis of proliferation and cytokine production by carboxyfluorescein succinimidyl ester (CFSE) dilution assay. Allergol Int 2007; 56(2): 149-55.
87. Pichler WJ, Yawalkar N, Britschgi M, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002; 3(4): 229-38.
88. Rozieres A, Vocanson M, Said BB, Nosbaum A, Nicolas JF. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol 2009; 9(4): 305-10.
89. Schaerli P, Britschgi M, Keller M, et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 2004; 173(3): 2151-8.
90. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28(3): 113-9.
91. Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9(1): 71-7.
92. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9(4): 316-21.
93. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007; 119(4): 973-81.
94. Luque I, Leyva L, Jose Torres M, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56(7): 611-8.
95. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59(8): 809-20.
96. Schnyder B, Pichler WJ. Skin and laboratory tests in amoxicillinand penicillin-induced morbilliform skin eruption. Clin Exp Allergy 2000; 30(4): 590-5.
97. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006; 118(4): 949-56.
98. Khalil G, El-Sabban M, Al-Ghadban S, et al. Cytokine expression profile of sensitized human T lymphocytes following in vitro stimulation with amoxicillin. Eur Cytokine Netw 2008; 19(3): 131-41.
99. Rozieres A, Hennino A, Rodet K, et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009; 64(4): 534-42.
100. El-Ghaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of T-cell clones from piperacillinhypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther 2012; 341(3): 597-610.
101. Elzagallaai AA, Knowles SR, Rieder MJ, et al. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther 2009; 13(5): 313-30.
102. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118(1): 233-41.
103. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drugspecific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111(6): 1393-403.
104. Tanvarasethee B, Buranapraditkun S, Klaewsongkram J. The potential of using enzyme-linked immunospot to diagnose cephalosporin-induced maculopapular exanthems. Acta Derm Venereol 2013; 93(1): 66-9.
105. Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol 2013; 168(3): 539-49.
106. Martin M, Wurpts G, Ott H, et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy 2010; 65(1): 32-9.
107. Sachs B, Erdmann S, Malte Baron J, et al. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 2002; 32(5): 736-44.
108. Cornejo-Garcia JA, Fernandez TD, Torres MJ, et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy 2007; 62(12): 1429-38.
109. Fernandez TD, Mayorga C, Torres MJ, et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy 2008; 63(6): 712-9.
110. Sanchez-Quintero MJ, Torres MJ, Blazquez AB, et al. Synergistic effect between amoxicillin and TLR ligands on dendritic cells from amoxicillin-delayed allergic patients. PLoS One 2013; 8(9): e74198.
111. Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T cell-mediated drug allergy. Clin Exp Allergy 2011; 41(4): 461-70.
112. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2(4): 325-31.
113. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9(4): 322-8.
114. Padial MA, Alvarez-Ferreira J, Tapia B, et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol 2004; 150(1): 139-42.
115. Homey B, Alenius H, Muller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8(2): 157-65.
116. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194(4): 398-405.
117. Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30(6): 847-55.
118. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 1994; 145(3): 550-60.
119. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14(12): 1343-50.
120. Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 2008; 158(6): 1230-8.
121. Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17(3): 201-8.
122. Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003; 91(1): 86-91.
123. Zawodniak A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010; 65(3): 376-84.
124. Nishio D, Izu K, Kabashima K, Tokura Y. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci 2007; 48(1): 25-33.
125. Posadas SJ, Leyva L, Torres MJ, et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000; 106(4): 769-76.
126. Thong BY, Mirakian R, Castells M, et al. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J 2011; 4(12): 257-70.
127. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63(3): 732-41.
128. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27(2): 175-81.
129. Mayorga C, Sanz ML, Gamboa P, et al. In vitro methods for diagnosing nonimmediate hypersensitivity reactions to drugs. J Investig Allergol Clin Immunol 2013; 23(4): 213-25; quiz precedeing 25.
130. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118(4): 728-33.
131. Chaves P, Torres MJ, Aranda A, et al. Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams. Allergy 2010; 65(12): 1600-8.
132. Lopez S, Torres MJ, Rodriguez-Pena R, et al. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. Br J Dermatol 2009; 160(2): 259-65.
133. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62(12): 1439-44.
134. Stander S, Metze D, Luger T, Schwarz T. [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review]. Hautarzt 2013; 64(8): 611-22; quiz 23-4.
135. Beeler AP, Pichler WJ. In vitro test of T-Cell-Mediated hypersensitivity. In: Pichler WJ, Ed. Drug Hypersensitivity. Basel: Karger 2007; pp. 380-90.
136. Maria VA, Pinto L, Victorino RM. Lymphocyte reactivity to exvivo drug antigens in drug-induced hepatitis. J Hepatol 1994; 21(2): 151-8.
137. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol 2010; 125(2): 411-18 e4.
138. Gomez E P-CG, Castell JV, Torres MJ, Blanca M, Mayorga C.. Effect of metabolising cell system in lymphocyte transformation test to evaluate non immediate reaction to anticonvulsants. Estambul: EAACI 2011.
139. Czerkinsky C, Moldoveanu Z, Mestecky J, Nilsson LA, Ouchterlony O. A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods 1988; 115(1): 31-7.
140. Porebski G, Pecaric-Petkovic T, Groux-Keller M, et al. In vitro drug causality assessment in Stevens-Johnson syndrome-alternatives for lymphocyte transformation test. Clin Exp Allergy 2013; 43(9): 1027-37.
141. Sanz ML, Mayorga C, Martínez-Aranguren R, Gamboa PM. Drug Hypersensitivity. USA: In Intech 2012; pp. 261-78.
142. Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ. Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity. Allergy 2009; 64(9): 1269-78.
143. Fu M, Gao Y, Pan Y, et al. Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain longlived IFN-gamma and sFasL memory response. PLoS One 2012; 7(9): e45516.
144. Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drugspecific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155(1): 462-72.
145. Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in druginduced cutaneous eruptions. J Allergy Clin Immunol 2000; 106(6): 1171-6.
146. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 2008; 63(2): 181-8.
147. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31(9): 1398-408.
148. Maino VC, Suni MA, Ruitenberg JJ. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 1995; 20(2): 127-33.
149. Merk HF. Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. Toxicology 2005; 209(2): 217-20.